January 15, 2026 a 01:00 pm
HOLX: Analysts Ratings - Hologic, Inc.
Hologic, Inc., a leader in diagnostic products, medical imaging, and surgical solutions, has experienced significant changes in analyst ratings over recent months. The company's multi-segment operations offer diversified revenue streams, yet the surge in 'Hold' ratings may indicate cautious market sentiment. Analysts seem to be reassessing growth potentials in light of recent economic fluctuations.
Historical Stock Grades
The recent analyst ratings for Hologic, Inc. indicate a dominance of 'Hold' recommendations, with 17 out of 20 analysts advising to hold the stock. This suggests a sentiment shift, as earlier months showed stronger buy inclinations. The absence of 'Sell' and 'Strong Sell' ratings illustrates cautious optimism.
| Rating | Number | Score |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 3 | |
| Hold | 17 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment around HOLX has shifted considerably over recent months. The substantial increase in 'Hold' ratings indicates growing caution, possibly due to market or company-specific challenges.
- The total ratings have remained relatively stable.
- 'Strong Buy' ratings decreased from 7 in 2024 to 0 by 2026.
- 'Hold' ratings surged from an average of 2 in early 2024 to 17 by early 2026.
- No ratings fall into 'Sell' or 'Strong Sell', showing no negative extreme sentiment.
Percentage Trends
Over the analyzed period, HOLX has seen a rebalancing of analyst opinions. The 'Strong Buy' category has dwindled, whereas the 'Hold' category now takes precedence.
- Early 2024 had nearly equal distributions between 'Strong Buy', 'Buy', and 'Hold'.
- By 2026, a significant shift towards a 'Hold' stance is evident, reflecting market caution.
- The percentage of 'Strong Buy' has gone from around 30% to 0%, with 'Hold' climbing from under 20% to 85%.
- This shift could suggest a re-evaluation of growth prospects amid challenging market conditions.
Latest Analyst Recommendations
Recent recommendations indicate a trend towards moderation, with many analysts downgrading their outlook on HOLX.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-12 | Hold | Buy | Argus Research |
| 2026-01-05 | In Line | Outperform | Evercore ISI Group |
| 2025-11-11 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-10-23 | Neutral | Outperform | Mizuho |
| 2025-10-22 | Market Perform | Outperform | Raymond James |
Analyst Recommendations with Change of Opinion
Further analysis shows a pattern of downgrades among top analysts, signaling a more cautious outlook on the stock.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-12 | Hold | Buy | Argus Research |
| 2026-01-05 | In Line | Outperform | Evercore ISI Group |
| 2025-10-23 | Neutral | Outperform | Mizuho |
| 2025-10-22 | Market Perform | Outperform | Raymond James |
| 2025-10-22 | Neutral | Overweight | JP Morgan |
Interpretation
The current analyst sentiment indicates an increasing wariness towards Hologic, Inc's growth prospects. A discernible trend towards more conservative recommendations such as 'Hold' and 'Neutral' suggests that analysts are hedging against potential market volatilities or company-specific challenges. While there is no strong bearish sentiment (no 'Sell' or 'Strong Sell' ratings), the transition from 'Strong Buy' to 'Hold' reflects uncertainties around the stock's near-term performance. The growing number of downgrades correlates with a more cautious market outlook.
Conclusion
In conclusion, Hologic, Inc. faces an increasingly cautious sentiment among analysts, evidenced by a shift to 'Hold' ratings. While the company's diversified operations offer resiliency, uncertainties in the market or within the company may temper bullish sentiments. Risk-averse investors may find comfort in the stable yet conservative analyst perspectives, whereas those seeking aggressive growth may exercise caution. The evolution of the ratings indicates a need for monitoring external and operational developments closely.